Member Info for Maba

The Board of Henderson Morley plc ("Henderson Morley"), the AIM quoted biotechnology company, is pleased to announce that it has received a Letter of Intent (LOI), from a specialist pharmaceutical company based outside the EU, for the purchase of the intellectual property rights (IPR) of some of Henderson Morley's human applications in the ICVT portfolio. Henderson Morley has been in discussions with this party for 8 months.

http://www.iii.co.uk/investment/detail?code=cotn:HML.L&it=le

Not sure that TIG would be willing to accept such a paltry sum when they have previously rebuffed similar offers. I too hope they hold out for more as this is a cracking stock with far more potential imo. You only have to look at both the quantum and quality of the recent contract wins to realise TIG has far more to it than a quick bail out. Lets hope there's no sale and we can see a steady rise beyong the 20p figures being quoted !

http://www.iii.co.uk/investment/detail?code=cotn:STP.L&it=le Upbeat results - looks good to me !

PRELIMINARY RESULTS FOR THE YEAR ENDED 30 APRIL 2009 SpiriTel plc (AIM: STP), the business communications group, is pleased to announce preliminary results for the year ended 30 April 2009. Commenting on the results, Chairman, Lord St. John of Bletso said: "I am pleased to report on a further year of growth and development for SpiriTel plc. The Company has made significant progress despite an increasingly tough operating environment which has seen several competitors fall by the wayside. As a fully integrated business communications provider delivering fixed, mobile, data and networking services to a substantial customer base the Group is very well placed to progress its chosen strategy of 'acquire, integrate, grow' to deliver increased shareholder value." Highlights: - Underlying EBITDA* 61% ahead of prior year at £1.5 million (2008: £0.9 million) - Revenue up 18% to £19.7 million (2008: £16.7 million) - Gross profit up 19% to £7.6 million (2008: £6.4 million) - Pre tax loss £1.7 million (2008: £4.0 million), after non-cash finance costs** of £0.8 million (2008: £3.1 million) - Post year end new 5 year debt and overdraft facility of £4.5m agreed with Clydesdale Bank - Earnings enhancing acquisition of ED Communications completed - Cross selling contracts signed worth £7 million over their term - Customer base increased to 2,337 at year end (2008: 1,525) - Post year

Chief Executive, Alastair Mills added: "We operate in a dynamic sector and the Board believes that we now stand at a particularly exciting point in the Company's development. We have demonstrated our ability to enhance earnings through acquisitions, followed up by significant cross-selling successes from our range of converged products and services into both new and existing customer bases. The foundations are in place to deliver ongoing value to shareholders and I look forward to the coming year with confidence."

The vaccine candidates will be tested in the model systems developed by internationally renowned Professor Rajiv Khanna, the Director of the ACVD. It is expected that preliminary results of these studies will be available within three months of receipt of the vaccine candidates.

Commenting, Executive Chairman, Andrew Knight said: "Our scientific team has spent the last 18 months working on the production of these important vaccine candidates, and we are pleased that we are now able to send these to the ACVD for further testing."

EPSTEIN BARR VIRUS VACCINE CANDIDATE UPDATE The Board of Henderson Morley plc ("Henderson Morley" or the "Company"), the Aim quoted biotechnology company, is pleased to announce that the scientific team lead by Dr. John Burden, has successfully produced vaccine candidates for Epstein Barr Virus ("EBV"). Numerous novel and innovative techniques have been employed in the production, purification and validation of the vaccine candidates. The product candidates have been validated and are ready for delivery to the Australian Centre for Vaccine Development ("ACVD") in Brisbane, once the appropriate regulatory permissions have been granted for import into Australia. It is anticipated that import permission will be granted in early October.

http://www.iii.co.uk/investment/detail?code=cotn:HML.L&display=news&it=le

LONR back on track !

Spiked up too much for me and I am out for now. Lets see how much further we can go but the real danger is selling once we top out. If all decide to sell on first retrace when no one is buying. Result a plummeting sp.

On the rise big time today

Very sensitive to news flow. With a market cap of £5.64M this is tiny. Any good news will see this fly out the blocks with the demand for shares far outstripping supply. One to watch and hold for sure !

been very subdued for a month or so and in last week or so we are seeing some very positive movement. I think Africa generally appears to have come back into the spotlight recently and should hopefully now gain some interest from investors again. Double figures once again would be nice. And a significant milestone en route recovery.

Nice one. I got in around a week ago too and now looking very good. Will be very interesting to see how high this goes when it eventually rises above the radar !

Love this stock. It releases good news on a regular basis. And the sp reacts positively. With all the recent contract wins this demonstrates the end users confidence in the product. I can see ever increasng biz being won. And an escalating sp on the back of these wins.

Another big rise today - still no RNS ?

Rising again. Is there news coming ?

Nice when preictions come to fruition. Happy Days !!!